Skip to content
thispeptide

MaxLife

MaxLife coordinates compounded semaglutide and tirzepatide injections with independent clinicians. Its public FDA-response page gives useful historical context, while the treating practice and laboratory arrangement need confirmation.

Review by Leah Garner, clinical-evidence editor · Updated October 2026

The short version

The current disclosures identify the platform and pharmacy roles more clearly than a generic physician-guided claim. Before joining, confirm the actual treating practice, monitoring and dose-related charges, and consider the FDA warning alongside the company’s stated corrective actions.

Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

FDA warning letter on record: Letter 721453 · February 2026

Lowest listed: Semaglutide injection, from $155/mo

Visit MaxLife →

MaxLife Technologies Inc. operates the patient-management platform. Its current resources explicitly describe compounded semaglutide and tirzepatide given as once-weekly injections. A licensed partner pharmacy prepares and dispenses the medicine; the platform is not the compounder.

What MaxLife prescribes, by goal

Weight

  • SemaglutideFDA-approved
    • Injection (compounded)From $155/mo
  • TirzepatideFDA-approved
    • Injection (compounded)From $195/mo

Both current offered medicines are compounded injections. The provider should explain the individual rationale, available approved alternatives and exact formulation. A vitamin additive or a shared active ingredient does not establish identical outcomes or lower side effects.

Each “From” figure is the seller’s own starting price, in the unit the seller states. Where a required fee or a package length changes what one month costs, the smaller line under it is our arithmetic, not a figure the seller prints. Compounded preparations are not FDA-approved.

Who prescribes

A licensed clinician

The terms distinguish the platform from independent affiliated medical groups and third-party practitioners, but the reviewed pages do not identify one clinical group or professional assigned to every patient. Ask for the practice name and the treating professional’s state license before care begins. A physician-guided headline does not establish a guaranteed physician appointment.

An online medical intake is followed by provider review. The FAQ says a two-way video visit is arranged when required by the patient’s state. Ongoing access includes messaging about dose adjustments and side-effect support, while a higher-dose request can involve a provider call. Ask about ordinary response times and how to obtain a live assessment when symptoms need one.

Are labs required?

Required tests and charges unconfirmed

The legal terms contemplate outside laboratories, but a universal required GLP-1 panel, testing interval or included laboratory allowance was not established. Ask what the prescriber needs before treatment and whether any ordered tests add to the plan price.

Ready to start with MaxLife?

Lowest listed price: Semaglutide injection, from $155/mo. Confirm it on the seller’s own site.

What it claims, and what it cites

FDA warning letter CMS 721453, dated February 20, 2026, concerned December 2025 website claims and pictured labeling. FDA said these misleadingly implied MaxLife compounded the drugs and that the compounds were approved, evaluated or equivalent to approved medicines. MaxLife says it submitted a response on February 24 and implemented corrective actions. Its August 31 update expressly does not claim FDA closeout. No agency closeout was confirmed. Current resources distinguish compounded preparations from branded-drug trial results. Other pages still make broad patient-result and tolerability claims. Those need evidence matching the actual prescription and population; selected testimonials are not an individualized prediction.

How it bills

The public monthly options are $155 for semaglutide and $195 for tirzepatide. The lower $89 and $120 headlines belong to three-month starter purchases, not unrestricted ongoing monthly rates. The program includes clinical review, medication, supplies and delivery, while laboratory costs remain unresolved. The FAQ says a higher dose can change the prescription and membership, so a guaranteed-fee label should not be assumed to cover every dose. Cancellation requires thirty days’ notice under the terms, and medication or partly used periods are generally nonrefundable.

For and against

  • For: Named pharmacy partners listed
  • For: Visit format and ongoing messaging described
  • For: Company publishes a substantive FDA-response statement
  • Against: Actual treating group and professional unconfirmed
  • Against: Dose-related membership adjustment needs clarification
  • Against: No FDA closeout confirmed for historical warning

The evidence behind what it sells

Right for

Someone who will verify clinical accountability and monitoring while comparing the regular monthly plan with a starter purchase.

Look elsewhere if

Someone expecting the starter headline to remain unchanged through every dose and renewal.

Other sellers for weight

MaxLife

Frequently asked questions

Is the first review always a live appointment?
The FAQ says an audiovisual visit is arranged when required by state rules. Confirm the format for your circumstances.
Did the company say FDA closed the warning?
No. Its August update describes corrective actions but expressly does not claim agency closeout.
Does a guaranteed fee prove all doses cost the same?
The FAQ also says a higher dose can change the prescription and membership. Obtain the actual dose-price schedule.

Sources

  • Current plan, clinical access and pharmacy list
  • Semaglutide monthly versus starter purchase
  • Tirzepatide monthly versus starter purchase
  • Provider relationship and thirty-day notice
  • Named offered injection forms and included services
  • Company response and stated unresolved FDA status
  • FDA historical labeling and approval-claim warning

See what MaxLife prescribes today

MaxLife sets its own prices, plans and the states it serves. Check them before you start.

Written by Leah Garner from MaxLife’s own public pages, against the published methodology. No outcome is claimed first-hand and no score is given. A partnership never changes what this page says; see how the site is paid.